Congenia Overview

  • Founded
  • 2004
  • Status
  • Private
  • Latest Deal Type
  • Buyout/​LBO
  • Investors
  • 1

Congenia General Information


Developer of bio pharmaceutical drugs designed to target the mitochondrial permeability transition pore (mPTP). The company's drugs are focused on developing inhibitors to stop the mitochondrial permeability transition that can lead to cell death, enabling patients and medical practitioners to clinically validate the pathogenesis of several diseases and other indications.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Via Privata Giovannino De Grassi, 11
  • 20123 Milan
  • Italy
+39 02 0000 0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Congenia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Buyout/LBO Completed Clinical Trials - General

Congenia Executive Team (5)

Name Title Board Seat Contact Info
Federica Draghi Ph.D Chief Operating Officer
Marco Giorgio Ph.D Co-Founder & Scientific Advisor
Paolo Bernardi Co-Founder & Scientific Advisor
Pier Pelicci Ph.D Co-Founder & Scientific Advisor
Saverio Minucci Co-Founder & Scientific Advisor

Congenia Investors (1)

To view Congenia‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Genextra Venture Capital Majority 000 0000 000000 0

Ready to get started?

Request a free trial